Heavy Metal-Free PEG Nanoconstructs for MRI and Photodynamic Therapy

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a long-standing need for innovative drugs, medical products, and imaging agents, particularly in cancer diagnoses and treatments, and for MRI imaging agents that do not rely on heavy metals.

Innovation Solution

Development of nanoconstructs comprising a backbone material with an active agent, such as a photosensitizer, attached to polyethylene glycol (PEG) nanoparticles, which have a narrow particle size distribution and are capable of performing therapy, imaging, and theranostic applications without using heavy metals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If heavy metals are used in MRI imaging agents, then imaging capability is improved, but toxicity increases

Engineering Contradiction:
Improveimaging capabilityVSAvoidtoxicity
Core Design Contradiction:
Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent removes heavy metals from the MRI imaging agent composition entirely, extracting the harmful component while preserving the essential imaging function through alternative materials that do not exhibit heavy metal toxicity

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses biodegradable and non-toxic materials that can be safely eliminated from the body, replacing persistent heavy metals with materials designed for safe metabolic clearance after serving their imaging purpose

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Productivity

If nanoparticle size is reduced to increase cellular uptake, then therapeutic efficacy is improved, but manufacturing precision becomes more difficult to control

Engineering Contradiction:
Improvecellular uptake efficiencyVSAvoidparticle size distribution control
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent employs precise control of synthesis parameters including monomer concentration, crosslinker ratio, polymerization temperature, and reaction time to achieve narrow particle size distributions in the 10-50 nm range, optimizing both cellular uptake and manufacturing consistency

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention uses pre-formed PEG nanoparticles with controlled sizes as templates before photosensitizer attachment, ensuring that the final conjugates maintain narrow size distributions while achieving the small dimensions needed for efficient cellular internalization

Inventive Principle:
Principle #10Preliminary action

3Power

If photosensitizer concentration is increased to improve photodynamic therapy efficacy, then reactive oxygen species production is improved, but off-target effects increase

Engineering Contradiction:
Improvereactive oxygen species productionVSAvoidoff-target effects
Core Design Contradiction:
PowerVSObject-generated harmful factors

Solution Approach 1:

The patent attaches photosensitizers to PEG nanoparticles with controlled density and spatial distribution, creating local concentrations that maximize ROS production at the target site while maintaining low overall systemic concentrations to minimize off-target effects

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The PEG nanoparticle acts as an intermediary carrier that delivers photosensitizers specifically to target cells through enhanced permeation and retention effects, concentrating the therapeutic agent where needed while reducing exposure to healthy tissues

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These nanoconstructs provide superior photodynamic therapy efficacy, are non-toxic, and serve as molecular imaging agents for MRI, offering improved reactive oxygen species production, targeted therapy, and safe, heavy metal-free imaging.

Implementation Method 1

utilizing photosensitizer (PS) molecules. When the photosensitizer is exposed to a specific wavelength of light, it produces a form of oxygen that kills nearby cells, e.g., reactive oxygen species

Methodology Applied
Scientific EffectPhotodynamic therapy: Photo-oxidation

Implementation Method 2

nuclear magnetic resonance; the nanoparticles are capable of being directly imaged by a magnetic field generated by a magnetic resonance imaging system

Methodology Applied
Scientific EffectMagnetic resonance: Magnetic Field

Data Source

PatentUS20230233715A1Small highly uniform nanomedicine compositions for therapeutic, imaging and theranostic applications
Publication Date: 2023.07.27 THE RGT UNIV OF MICHIGAN
  • US20230233715A1 patent drawing
  • US20230233715A1 patent drawing
  • US20230233715A1 patent drawing

AI summary

A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal.